These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31251792)

  • 1. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis.
    Beumer W; Swildens J; Leal T; Noel S; Anthonijsz H; van der Horst G; Kuiperij-Boersma H; Potman M; van Putten C; Biasutto P; Platenburg G; de Jonge H; Henig N; Ritsema T
    PLoS One; 2019; 14(6):e0219182. PubMed ID: 31251792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.
    Sermet-Gaudelus I; Clancy JP; Nichols DP; Nick JA; De Boeck K; Solomon GM; Mall MA; Bolognese J; Bouisset F; den Hollander W; Paquette-Lamontagne N; Tomkinson N; Henig N; Elborn JS; Rowe SM
    J Cyst Fibros; 2019 Jul; 18(4):536-542. PubMed ID: 30467074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cystic Fibrosis-Like Airway Surface Layer Is not a Significant Barrier for Delivery of Eluforsen to Airway Epithelial Cells.
    Brinks V; Lipinska K; de Jager M; Beumer W; Button B; Livraghi-Butrico A; Henig N; Matthee B
    J Aerosol Med Pulm Drug Deliv; 2019 Oct; 32(5):303-316. PubMed ID: 31120356
    [No Abstract]   [Full Text] [Related]  

  • 4. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.
    Drevinek P; Pressler T; Cipolli M; De Boeck K; Schwarz C; Bouisset F; Boff M; Henig N; Paquette-Lamontagne N; Montgomery S; Perquin J; Tomkinson N; den Hollander W; Elborn JS
    J Cyst Fibros; 2020 Jan; 19(1):99-107. PubMed ID: 31182369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
    Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
    Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced expression of Tis7/IFRD1 protein in murine and human cystic fibrosis airway epithelial cell models homozygous for the F508del-CFTR mutation.
    Blanchard E; Marie S; Riffault L; Bonora M; Tabary O; Clement A; Jacquot J
    Biochem Biophys Res Commun; 2011 Aug; 411(3):471-6. PubMed ID: 21723850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis.
    Bergougnoux A; Petit A; Knabe L; Bribes E; Chiron R; De Sario A; Claustres M; Molinari N; Vachier I; Taulan-Cadars M; Bourdin A
    Int J Biochem Cell Biol; 2017 Jul; 88():124-132. PubMed ID: 28478266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.
    De Stefano D; Villella VR; Esposito S; Tosco A; Sepe A; De Gregorio F; Salvadori L; Grassia R; Leone CA; De Rosa G; Maiuri MC; Pettoello-Mantovani M; Guido S; Bossi A; Zolin A; Venerando A; Pinna LA; Mehta A; Bona G; Kroemer G; Maiuri L; Raia V
    Autophagy; 2014; 10(11):2053-74. PubMed ID: 25350163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells.
    Stanke F; van Barneveld A; Hedtfeld S; Wölfl S; Becker T; Tümmler B
    Eur J Hum Genet; 2014 May; 22(5):660-6. PubMed ID: 24105369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Inhibition of the Membrane-Bound Transcription Factor Site-1 Protease (MBTP1) Alleviates the p.Phe508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Defects in Cystic Fibrosis Cells.
    Santinelli R; Benz N; Guellec J; Quinquis F; Kocas E; Thomas J; Montier T; Ka C; Luczka-Majérus E; Sage E; Férec C; Coraux C; Trouvé P
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells.
    Michaels WE; Bridges RJ; Hastings ML
    Nucleic Acids Res; 2020 Jul; 48(13):7454-7467. PubMed ID: 32520327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR.
    Matos AM; Gomes-Duarte A; Faria M; Barros P; Jordan P; Amaral MD; Matos P
    Sci Rep; 2018 Aug; 8(1):13026. PubMed ID: 30158635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.